Mental disorders of known aetiology and precision medicine in psychiatry: a promising but neglected alliance
Year: 2016
Type: article
Abstract: Personalized or precision medicine is predicated on the assumption that the average response to treatment is not necessarily representative of the response of each individual. A commitment to personalized medicine demands an effort to bring evidence-based medicine and personalized medicine closer together. The use of relatively homogeneous groups, defined using a priori criteria, may constitute a promising initial step for developing more accurate risk-prediction models with which to advance the development of personalized evidence-based medicine approaches to heterogeneous syndromes such as schizophrenia. However, this can lead to a paradoxical situation in the field of psychiatry. Since there has been a tendency to loosely define psychiatric disorders as ones without a known aetiology, the discovery of an aetiology for psychiatric syndromes (e.g. 22q11.2 deletion syndrome in some cases of schizophrenia), while offering a path toward more precise treatments, may also lead to their reclassification away from psychiatry. We contend that psychiatric disorders with a known aetiology should not be removed from the field of psychiatry. This knowledge should be used instead to guide treatment, inasmuch as psychotherapies, pharmacotherapies and other treatments can all be valid approaches to mental disorders. The translation of the personalized clinical approach inherent to psychiatry into evidence-based precision medicine can lead to the development of novel treatment options for mental disorders and improve outcomes.
Source: Psychological Medicine
Institutions: Universidad Complutense de Madrid, Hospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Investigación Sanitaria Gregorio Marañón, University of California, San Francisco, Langley Porter Psychiatric Hospital and Clinics, Cardiff University, University of Pennsylvania
Language: English
Topic: Mental Health and Psychiatry
Subfield: Philosophy
Field: Arts and Humanities
Domain: Social Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, Fundación Mutua Madrileña, Fundación Alicia Koplowitz, European Commission, Ministerio de Economía y Competitividad, Ministerio de Ciencia e Innovación, Centro de Investigación Biomédica en Red de Salud Mental, Servier, H. Lundbeck A/S, Pfizer Pharmaceuticals, Medical Research Council, Instituto de Salud Carlos III, National Institute of Mental Health, FP7 Health, Cilag
Awards: G1874133415, G1897392993, Molecular Genetic Studies of Schizophrenia, Translating neuroimaging findings from research into clinical practice, G4827590587, 5/5 International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome, MRC Centre for Neuropsychiatric Genetics and Genomics, OPtimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE), G6844935297, G7192275438, Neuroimaging platform for characterisation of metabolic co-morbidities in psychotic disorders, European Network of National Schizophrenia Networks Studying Gene-Environment Interactions, G85705433
OpenAlex ID: W2462104784
